{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:38:48Z","timestamp":1770745128281,"version":"3.49.0"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"08","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BAY 94-9027 (damoctocog alfa pegol, Jivi) is an extended-half-life recombinant factor VIII (rFVIII) shown to be well-tolerated and efficacious in bleeding prevention in previously treated patients with severe hemophilia A. During the PROTECT VIII study, prophylaxis patients received BAY 94-9027 at intervals determined based on their bleeding phenotype, observed during a 10-week run-in treatment period with twice-weekly dosing. Those with \u2264 1 spontaneous joint or muscle bleed were randomized to either 45 to 60\u2009IU\/kg every 5 days or 60\u2009IU\/kg every 7 days; patients could increase dosing frequency to every 5 days or twice weekly in the case of bleeds. Those enrolled after the randomization arms were full, and those with \u2265 2 bleeds in the run-in period, received 30 to 40\u2009IU\/kg twice weekly. Patients completing the main study could receive open-label BAY 94-9027 in the extension phase. Dosing regimen, total, and joint annualized bleeding rates were analyzed over three periods: prestudy, main study, and extension. A total of 80 patients who were on prophylaxis treatment prior to and during the study and had prior bleed data available were evaluated in this post hoc analysis of PROTECT VIII. Most patients (&gt; 80%) required fewer infusions with BAY 94-9027 prophylaxis versus their previous standard-half-life (SHL) rFVIII product. Lower bleeding and joint bleeding rates were observed over time from the prestudy to the extension study period in all treatment regimens. Compared with SHL FVIII, BAY 94-9027 prophylaxis allows patients to reduce infusion frequency with maintained or improved protection from bleeds.<\/jats:p>","DOI":"10.1055\/a-1333-5536","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:14:14Z","timestamp":1607559254000},"page":"1079-1086","source":"Crossref","is-referenced-by-count":6,"title":["Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis"],"prefix":"10.1055","volume":"121","clinical-trial-number":[{"clinical-trial-number":"nct01580293","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-4028","authenticated-orcid":false,"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[{"name":"Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center\u2013IRCCS, Rozzano, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Reding","sequence":"additional","affiliation":[{"name":"University of Minnesota Medical Center, Minneapolis, Minnesota, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Negrier","sequence":"additional","affiliation":[{"name":"Louis Pradel University Hospital, University Claude Bernard Lyon 1, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryce A.","family":"Kerlin","sequence":"additional","affiliation":[{"name":"Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savita","family":"Rangarajan","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, Illinois, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,2,28]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"A Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"A Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"M J Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs","volume":"236","author":"L M Aledort","year":"1994","journal-title":"J Intern Med"},{"issue":"S 01","key":"ref5","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1111\/jth.12929","article-title":"Half-life extended factor VIII for the treatment of hemophilia A","volume":"13","author":"A Tiede","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"S Bj\u00f6rkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2516.2006.01189.x","article-title":"Practice patterns in haemophilia A therapy -- global progress towards optimal care","volume":"12","author":"S Geraghty","year":"2006","journal-title":"Haemophilia"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1586\/17474086.2015.1002465","article-title":"Individualizing prophylaxis in hemophilia: a review","volume":"8","author":"P Petrini","year":"2015","journal-title":"Expert Rev Hematol"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"P W Collins","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref10","first-page":"141","article-title":"Extended half-life coagulation factors: a new era in the management of hemophilia patients","volume":"36","author":"M C Ar","year":"2019","journal-title":"Turk J Haematol"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2009-11-254755","article-title":"Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment","volume":"116","author":"B Mei","year":"2010","journal-title":"Blood"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A","volume":"12","author":"T E Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13597","article-title":"Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII","volume":"15","author":"M T Reding","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref14","first-page":"32","article-title":"Effective protection for >5 years with BAY 94-9027 prophylaxis: interim results from the PROTECT VIII extension trial. Poster Presentations","volume":"24","author":"G Thomson","year":"2018","journal-title":"Haemophilia"},{"key":"ref15","first-page":"x","article-title":"Safety of long-term prophylaxis with BAY 94-9027: interim results of >5 years of treatment in the PROTECT VIII extension trial","volume":"24","author":"M T Reding","year":"2018","journal-title":"Haemophilia"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/JBM.S206806","article-title":"Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A","volume":"10","author":"K Batt","year":"2019","journal-title":"J Blood Med"},{"issue":"06","key":"ref20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/hae.13853","article-title":"BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results","volume":"25","author":"S Lalezari","year":"2019","journal-title":"Haemophilia"},{"issue":"09","key":"ref21","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/j.1538-7836.2010.03962.x","article-title":"Blood-induced joint disease: the pathophysiology of hemophilic arthropathy","volume":"8","author":"L A Valentino","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"S 04","key":"ref22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2516.2004.00976.x","article-title":"The target joint","volume":"10","author":"K Mulder","year":"2004","journal-title":"Haemophilia"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/vox.12066","article-title":"Secondary prophylaxis vs. on-demand treatment to improve quality of life in severe adult haemophilia A patients: a prospective study in a single centre","volume":"106","author":"J A Aznar","year":"2014","journal-title":"Vox Sang"},{"issue":"S 03","key":"ref24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2516.2006.01268.x","article-title":"Pathogenesis of haemophilic arthropathy","volume":"12","author":"G Roosendaal","year":"2006","journal-title":"Haemophilia"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1111\/hae.13982","article-title":"Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027","volume":"26","author":"M T Reding","year":"2020","journal-title":"Haemophilia"},{"issue":"03","key":"ref26","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/hae.13432","article-title":"Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B","volume":"24","author":"C Wang","year":"2018","journal-title":"Haemophilia"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/hae.13221","article-title":"Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates","volume":"23","author":"S von Mackensen","year":"2017","journal-title":"Haemophilia"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/hae.13561","article-title":"BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: comprehensive pharmacokinetic assessment from clinical studies","volume":"24","author":"A Shah","year":"2018","journal-title":"Haemophilia"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/hae.12905","article-title":"Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis","volume":"22","author":"L A Valentino","year":"2016","journal-title":"Haemophilia"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1333-5536.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T14:18:29Z","timestamp":1660141109000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1333-5536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":26,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2021,7,29]]},"published-print":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1333-5536","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,9]]},"published":{"date-parts":[[2020,12,9]]}}}